Cutaneous Squamous Cell Carcinoma

Oncology
5
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 1 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
3 programs
1
1
CemiplimabPhase 2Monoclonal Antibody
CemiplimabPhase 1/2Monoclonal Antibody1 trial
cemiplimabN/AMonoclonal Antibody
Active Trials
NCT04339062Completed12Est. Mar 2025
One Biosciences
One BiosciencesFrance - Paris
1 program
1
ImgatuzumabPhase 2Monoclonal Antibody
Centessa Pharmaceuticals
1 program
1
ImgatuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04985825WithdrawnEst. Aug 2022
Shattuck Labs
Shattuck LabsAUSTIN, TX
1 program
1
Drug: SL-172154Phase 11 trial
Active Trials
NCT04502888TerminatedEst. Apr 2022
Sanofi
SanofiPARIS, France
1 program
cemiplimabN/AMonoclonal Antibody1 trial
Active Trials
NCT03492489No Longer Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Centessa PharmaceuticalsImgatuzumab
RegeneronCemiplimab
Shattuck LabsDrug: SL-172154

Clinical Trials (4)

Total enrollment: 12 patients across 4 trials

NCT04985825Centessa PharmaceuticalsImgatuzumab

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Start: Dec 2021Est. completion: Aug 2022
Phase 2Withdrawn
NCT04339062RegeneronCemiplimab

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Start: Nov 2020Est. completion: Mar 202512 patients
Phase 1/2Completed
NCT04502888Shattuck LabsDrug: SL-172154

Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

Start: Sep 2020Est. completion: Apr 2022
Phase 1Terminated
NCT03492489Sanoficemiplimab

Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

N/ANo Longer Available

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Monoclonal Antibody is the dominant modality (100% of programs)
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)